logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produswest2
Neglected tropical diseases in 2023 | Collections | MSF Science Portal

Each year hundreds of thousands of people die from a neglected tropical disease, while many more suffer serious illness or lifelong disability. Yet as we mark World Neglected Tropical Diseases (NTD) Day on 30th January 2023, global progress towards eliminating these diseases is threatened by shifting global health priorities and declining investment in the wake of the Covid-19 pandemic.


The content collection linked below offers a snapshot of MSF’s work over the past two years on managing some of the most deadly NTDs, finding better tools and models of care for highly affected populations, and advocating for greater access to care and increased global funding. Several authors describe our programs and lessons learned from a decade of treating snakebite victims in sub-Saharan Africa. Two studies evaluate shorter, less toxic treatment for visceral leischmaniasis, while a policy analysis proposes critical steps towards eliminating this horrific disease in East Africa. Last, reports from Sokoto, Nigeria describe the collaborative development of a comprehensive model of care for noma.

Collection Content

Journal Article
|
Commentary

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues

Potet J, Singh SN, Ritmeijer KKD, Sisay K, Alcoba G,  et al.
2022-12-21 • Toxicon: X
2022-12-21 • Toxicon: X
The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each y...
Conference Material
|
Abstract

Noma discharge toolkit - a person-centred approach to improve continuity of care

Ajamah S, Tanaka M, De Vore K, Vogiazou Y, Joseph S,  et al.
2022-11-26 • MSF Paediatric Days 2022
2022-11-26 • MSF Paediatric Days 2022
BACKGROUND AND AIMS
The Noma hospital in Sokoto State, Nigeria, provides specialised care for noma, a rapidly progressive and often fatal necrotising bacterial disease, which continu...
Journal Article
|
Research

AmBisome monotherapy and combination AmBisome - miltefosine therapy for the treatment of visceral leishmaniasis in patients co-infected with HIV in India: a randomised open label, parallel arm, phase 3 trial

Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Visceral leishmaniasis (VL) in patients living with Human-Immunodeficiency-Virus (HIV) present an increasingly important patient cohort in areas where both infections are ...
Journal Article
|
Research

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD,  et al.
2022-09-27 • Clinical Infectious Diseases
2022-09-27 • Clinical Infectious Diseases
BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...
Journal Article
|
Research

The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001–2018

Naylor-Leyland G, Collin SM, Gatluak F, den Boer ML, Alves F,  et al.
2022-08-18 • PLOS Neglected Tropical Diseases
2022-08-18 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral Leishmaniasis (VL) is endemic in South Sudan, manifesting periodically in major outbreaks. Provision of treatment during endemic periods and as an emergency respo...
Journal Article
|
Review

Towards the elimination of visceral leishmaniasis as a public health problem in East Africa: reflections on an enhanced control strategy and a call for action

Alvar J, den Boer ML, Dagne DA
2021-12-01 • Lancet Global Health
2021-12-01 • Lancet Global Health
East Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases globally that were reported to WHO in 2018, with an annual incidence that is only sli...
Journal Article
|
Review

Access to antivenoms in the developing world: a multidisciplinary analysis

Potet J, Beran D, Ray N, Alcoba G, Habib AG,  et al.
2021-10-26 • Toxicon: X
2021-10-26 • Toxicon: X
Access to safe, effective, quality-assured antivenom products that are tailored to endemic venomous snake species is a crucial component of recent coordinated efforts to reduce the globa...
Journal Article
|
Commentary

Control of visceral leishmaniasis in East Africa: fragile progress, new threats

Dahl EH, Hamdan M, Mabrouk L, Matendechero S, Mengistie TB,  et al.
2021-08-13 • BMJ Global Health
2021-08-13 • BMJ Global Health
SUMMARY BOX

• Significant progress has been made in reducing the global burden of visceral leishmaniasis, but new threats are on the horizon.
• Funding for elimination of ...
Journal Article
|
Commentary

Model of care, Noma Children’s Hospital, northwest Nigeria

Isah S, Amirtharajah M, Farley ES, Adetunji AS, Samuel J,  et al.
2021-06-03 • Tropical Medicine and International Health
2021-06-03 • Tropical Medicine and International Health
The Nigerian Ministry of Health has been offering care for noma patients for many years at the Noma Children's Hospital (NCH) in Sokoto, northwest Nigeria, and Médecins Sans Frontières h...
Conference Material
|
Poster

Outcomes and effectiveness of antivenom treatments in snakebite patients in north-west Ethiopia: retrospective cohort

Steegemans IM, Sisay K, Nshimiyimana E, Gebrewold G, Piening T,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research

See more collections

World Hepatitis Day 2022

World Hepatitis Day 2022
Each year hundreds of millions of people suffer from chronic or acute liver disease caused by hepatitis viruses, and over one million die. To mark World Hepatitis Day (July 28th) we bring you a selection of MSF research exploring how to better prevent, identify and treat hepatitis infection in lower-income countries and emergency contexts where the burden is heaviest. For example, in a South Sudanese camp for displaced people—a type of setting where poor sanitation and water quality regularly lead to hepatitis E outbreaks—MSF and the Ministry of Health (MoH) are conducting the world’s first reactive vaccination campaign against this disease, and evaluating the process and outcomes. In Cambodia, MSF and MoH collaborators found that a simplified community-based model of care for hepatitis C was safe and highly effective in diagnosing patients and in curing them with new antiviral drugs. It was also cost-effective, according to studies in several countries and patient populations. And these new drugs were safe and effective even in patients also being treated for drug-resistant tuberculosis.
MSF logo

Homepage featured
No description available
MSF logo

MSF Scientific Days Asia 2024

MSF Scientific Days Asia 2024 is a conference that presents research, innovation, and experiences from treatment and humanitarian programmes across Asia. MSF Scientific Days brings together researchers, practitioners, academics, and patient representatives with the aim to catalyse improvements in the quality of care provided to patients and populations at risk. This is a platform for experts in the humanitarian global health field to come together, collaborate, and discuss the current trends and challenges in innovation and healthcare. 

View All Collections
Neglected tropical diseases in 2023

Neglected tropical diseases in 2023